Inflammatory Bowel Disease (IBD) Management

There are two main reasons patients travel for IBD care: cost and access. Biologic therapies such as infliximab (Remicade) or vedolizumab can cost USD 15,000–30,000 per year in the US or Europe. The same FDA/EMA-approved biosimilars are available at partner centers in India and Turkey for 70–85% less. Second, patients in countries with limited gastroenterology expertise often cannot access IBD specialists, advanced diagnostics (MRI enterography, capsule endoscopy), or the full range of biologic agents. Our partner centers have dedicated IBD clinics with gastroenterologists who sub-specialize exclusively in Crohn's and ulcerative colitis.